News | Heart Failure | September 18, 2019

FDA Grants Fast Track Designation for Farxiga in Heart Failure

FDA approves accelerated development for dapagliflozin for adults with heart failure with reduced ejection fraction or preserved ejection fraction

FDA Grants Fast Track Designation for Farxiga in Heart Failure

September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure. The designation applies to adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

The FDA’s Fast Track program is designed to accelerate the development and review of new medicines for the treatment of serious conditions where there is an unmet treatment need.

The Fast Track designation is based on two Phase III trials, DAPA-HF and DELIVER, which investigated the role of FARXIGA in patients with heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively. The results of DAPA-HF, presented at the 2019 European Society of Cardiology (ESC) Congress, Aug. 31-Sept. 4 in Paris, France, showed Farxiga reduced the composite of CV death or worsening of heart failure by 26 percent (p<0.0001) and showed a reduction in each of the individual components of the composite endpoint.

Farxiga is currently approved as a monotherapy and as part of combination therapy to improve glycemic control in adults with type 2 diabetes (T2D). In August 2019 the FDA granted Fast Track designation for the development of Farxiga to delay the progression of renal failure and prevent CV and renal death in patients with chronic kidney disease. Farxiga is not indicated to reduce the risk of HF, CV death or kidney disease.

Read the article “Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure”

FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations — October 2019 update

For more information: www.escardio.org

Related Content

News | ESC

May 9, 2022 — Heart failure presents differently in women and men – discover the latest evidence and its impact on ...

Home May 09, 2022
Home
News | ESC

March 31, 2022 — The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held ...

Home March 31, 2022
Home
News | ESC

January 3, 2022 — The following is a list of the 2021 news stories from the European Society of Cardiology (ESC) ...

Home January 03, 2022
Home
News | ESC | By Dave Fornell, DAIC Editor

October 4, 2021 — Here are links to all the late-breaking cardiology studies presented in Hot-Line sessions at the 2021 ...

Home October 04, 2021
Home
News | ESC

The European Society of Cardiology (ESC) will host several Hot Lines sessions that will include some of the latest ...

Home July 21, 2020
Home
News | ESC

May 6, 2020 — The European Society of Cardiology (ESC), one of the world's largest cardiovascular conferences, is ...

Home May 06, 2020
Home
Feature | ESC

September 9, 2019 — More than 33,000 health professionals gathered over five days to attend the 2019 European Society of ...

Home September 09, 2019
Home
News | ESC

September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by ...

Home September 12, 2017
Home
News | ESC

September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively ...

Home September 12, 2017
Home
Feature | ESC

September 7, 2017 — Oxygen therapy does not improve survival in patients with heart attack symptoms, according to late ...

Home September 07, 2017
Home
Subscribe Now